Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Brain
Published in: Molecular Brain 1/2012

Open Access 01-12-2012 | Research

Mitochondrial dysfunction associated with increased oxidative stress and α-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue

Authors: Yoichi Imaizumi, Yohei Okada, Wado Akamatsu, Masato Koike, Naoko Kuzumaki, Hideki Hayakawa, Tomoko Nihira, Tetsuro Kobayashi, Manabu Ohyama, Shigeto Sato, Masashi Takanashi, Manabu Funayama, Akiyoshi Hirayama, Tomoyoshi Soga, Takako Hishiki, Makoto Suematsu, Takuya Yagi, Daisuke Ito, Arifumi Kosakai, Kozo Hayashi, Masanobu Shouji, Atsushi Nakanishi, Norihiro Suzuki, Yoshikuni Mizuno, Noboru Mizushima, Masayuki Amagai, Yasuo Uchiyama, Hideki Mochizuki, Nobutaka Hattori, Hideyuki Okano

Published in: Molecular Brain | Issue 1/2012

Login to get access

Abstract

Background

Parkinson’s disease (PD) is a neurodegenerative disease characterized by selective degeneration of dopaminergic neurons in the substantia nigra (SN). The familial form of PD, PARK2, is caused by mutations in the parkin gene. parkin-knockout mouse models show some abnormalities, but they do not fully recapitulate the pathophysiology of human PARK2.

Results

Here, we generated induced pluripotent stem cells (iPSCs) from two PARK2 patients. PARK2 iPSC-derived neurons showed increased oxidative stress and enhanced activity of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. iPSC-derived neurons, but not fibroblasts or iPSCs, exhibited abnormal mitochondrial morphology and impaired mitochondrial homeostasis. Although PARK2 patients rarely exhibit Lewy body (LB) formation with an accumulation of α-synuclein, α-synuclein accumulation was observed in the postmortem brain of one of the donor patients. This accumulation was also seen in the iPSC-derived neurons in the same patient.

Conclusions

Thus, pathogenic changes in the brain of a PARK2 patient were recapitulated using iPSC technology. These novel findings reveal mechanistic insights into the onset of PARK2 and identify novel targets for drug screening and potential modified therapies for PD.
Appendix
Available only for authorised users
Literature
1.
Farrer MJ: Genetics of Parkinson disease: paradigm shifts and future prospects. Nature reviews. 2006, 7: 306-318.CrossRefPubMed
2.
Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N: Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998, 392: 605-608. 10.1038/33416.CrossRefPubMed
3.
Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K, Suzuki T: Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet. 2000, 25: 302-305. 10.1038/77060.CrossRefPubMed
4.
Whitworth AJ, Pallanck LJ: The PINK1/Parkin pathway: a mitochondrial quality control system?. J Bioenerg Biomembr. 2009, 41: 499-503. 10.1007/s10863-009-9253-3.CrossRefPubMed
5.
Youle RJ, Narendra DP: Mechanisms of mitophagy. Nat Rev Mol Cell Biol. 2011, 12: 9-14. 10.1038/nrm3028.CrossRefPubMed
6.
Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA, Bhatnagar A, Meloni EG, Wu N, Ackerson LC, Klapstein GJ, et al: Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem. 2003, 278: 43628-43635. 10.1074/jbc.M308947200.CrossRefPubMed
7.
Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C, Wacker M, Klose J, Shen J: Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem. 2004, 279: 18614-18622. 10.1074/jbc.M401135200.CrossRefPubMed
8.
Perez FA, Palmiter RD: Parkin-deficient mice are not a robust model of parkinsonism. Proc Natl Acad Sci USA. 2005, 102: 2174-2179. 10.1073/pnas.0409598102.PubMedCentralCrossRefPubMed
9.
Sato S, Chiba T, Nishiyama S, Kakiuchi T, Tsukada H, Hatano T, Fukuda T, Yasoshima Y, Kai N, Kobayashi K, et al: Decline of striatal dopamine release in parkin-deficient mice shown by ex vivo autoradiography. J Neurosci Res. 2006, 84: 1350-1357. 10.1002/jnr.21032.CrossRefPubMed
10.
Jiang H, Ren Y, Yuen EY, Zhong P, Ghaedi M, Hu Z, Azabdaftari G, Nakaso K, Yan Z, Feng J: Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells. Nat Commun. 2012, 3: 668-PubMedCentralCrossRefPubMed
11.
Mattis VB, Svendsen CN: Induced pluripotent stem cells: a new revolution for clinical neurology?. Lancet Neurol. 2011, 10: 383-394. 10.1016/S1474-4422(11)70022-9.CrossRefPubMed
12.
Farrer M, Chan P, Chen R, Tan L, Lincoln S, Hernandez D, Forno L, Gwinn-Hardy K, Petrucelli L, Hussey J, et al: Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol. 2001, 50: 293-300. 10.1002/ana.1132.CrossRefPubMed
13.
Savitt JM, Dawson VL, Dawson TM: Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest. 2006, 116: 1744-1754. 10.1172/JCI29178.PubMedCentralCrossRefPubMed
14.
Ohta S, Imaizumi Y, Okada Y, Akamatsu W, Kuwahara R, Ohyama M, Amagai M, Matsuzaki Y, Yamanaka S, Okano H, Kawakami Y: Generation of human melanocytes from induced pluripotent stem cells. PLoS One. 2011, 6: e16182-10.1371/journal.pone.0016182.PubMedCentralCrossRefPubMed
15.
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007, 131: 861-872. 10.1016/j.cell.2007.11.019.CrossRefPubMed
16.
Matigian N, Abrahamsen G, Sutharsan R, Cook AL, Vitale AM, Nouwens A, Bellette B, An J, Anderson M, Beckhouse AG, et al: Disease-specific, neurosphere-derived cells as models for brain disorders. Dis Model Mech. 2010, 3: 785-798. 10.1242/dmm.005447.CrossRefPubMed
17.
Nguyen HN, Byers B, Cord B, Shcheglovitov A, Byrne J, Gujar P, Kee K, Schule B, Dolmetsch RE, Langston W, et al: LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell. 2011, 8: 267-280. 10.1016/j.stem.2011.01.013.PubMedCentralCrossRefPubMed
18.
Sies H: Glutathione and its role in cellular functions. Free Radic Biol Med. 1999, 27: 916-921. 10.1016/S0891-5849(99)00177-X.CrossRefPubMed
19.
Williamson TP, Johnson DA, Johnson JA: Activation of the Nrf2-ARE pathway by siRNA knockdown of Keap1 reduces oxidative stress and provides partial protection from MPTP-mediated neurotoxicity. Neurotoxicology. 2012, 33: 272-279. 10.1016/j.neuro.2012.01.015.PubMedCentralCrossRefPubMed
20.
Ramsey CP, Glass CA, Montgomery MB, Lindl KA, Ritson GP, Chia LA, Hamilton RL, Chu CT, Jordan-Sciutto KL: Expression of Nrf2 in neurodegenerative diseases. J Neuropathol Exp Neurol. 2007, 66: 75-85. 10.1097/nen.0b013e31802d6da9.PubMedCentralCrossRefPubMed
21.
Tufekci KU, Civi Bayin E, Genc S, Genc K: The Nrf2/ARE Pathway: a promising target to counteract mitochondrial dysfunction in parkinson's disease. Parkinsons Dis. 2011, 2011: 314082-PubMedCentralPubMed
22.
Fukae J, Mizuno Y, Hattori N: Mitochondrial dysfunction in Parkinson's disease. Mitochondrion. 2007, 7: 58-62. 10.1016/j.mito.2006.12.002.CrossRefPubMed
23.
Schapira AH: Mitochondrial dysfunction in neurodegenerative disorders. Biochim Biophys Acta. 1998, 1366: 225-233. 10.1016/S0005-2728(98)00115-7.CrossRefPubMed
24.
Greene JC, Whitworth AJ, Kuo I, Andrews LA, Feany MB, Pallanck LJ: Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci USA. 2003, 100: 4078-4083. 10.1073/pnas.0737556100.PubMedCentralCrossRefPubMed
25.
Mortiboys H, Thomas KJ, Koopman WJ, Klaffke S, Abou-Sleiman P, Olpin S, Wood NW, Willems PH, Smeitink JA, Cookson MR, Bandmann O: Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts. Ann Neurol. 2008, 64: 555-565. 10.1002/ana.21492.PubMedCentralCrossRefPubMed
26.
Matsuda N, Sato S, Shiba K, Okatsu K, Saisho K, Gautier CA, Sou YS, Saiki S, Kawajiri S, Sato F, et al: PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J Cell Biol. 2010, 189: 211-221. 10.1083/jcb.200910140.PubMedCentralCrossRefPubMed
27.
Narendra D, Tanaka A, Suen DF, Youle RJ: Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol. 2008, 183: 795-803. 10.1083/jcb.200809125.PubMedCentralCrossRefPubMed
28.
Tanaka A: Parkin-mediated selective mitochondrial autophagy, mitophagy: Parkin purges damaged organelles from the vital mitochondrial network. FEBS Lett. 2010, 584: 1386-1392. 10.1016/j.febslet.2010.02.060.PubMedCentralCrossRefPubMed
29.
Yoshii SR, Kishi C, Ishihara N, Mizushima N: Parkin mediates proteasome-dependent protein degradation and rupture of the outer mitochondrial membrane. J Biol Chem. 2011, 286: 19630-19640. 10.1074/jbc.M110.209338.PubMedCentralCrossRefPubMed
30.
Seibler P, Graziotto J, Jeong H, Simunovic F, Klein C, Krainc D: Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells. J Neurosci. 2011, 31: 5970-5976. 10.1523/JNEUROSCI.4441-10.2011.PubMedCentralCrossRefPubMed
31.
32.
Pramstaller PP, Schlossmacher MG, Jacques TS, Scaravilli F, Eskelson C, Pepivani I, Hedrich K, Adel S, Gonzales-McNeal M, Hilker R, et al: Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers. Ann Neurol. 2005, 58: 411-422. 10.1002/ana.20587.CrossRefPubMed
33.
Sasaki S, Shirata A, Yamane K, Iwata M: Parkin-positive autosomal recessive juvenile Parkinsonism with alpha-synuclein-positive inclusions. Neurology. 2004, 63: 678-682. 10.1212/01.WNL.0000134657.25904.0B.CrossRefPubMed
34.
Schlossmacher MG, Frosch MP, Gai WP, Medina M, Sharma N, Forno L, Ochiishi T, Shimura H, Sharon R, Hattori N, et al: Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol. 2002, 160: 1655-1667. 10.1016/S0002-9440(10)61113-3.PubMedCentralCrossRefPubMed
35.
Chung KK, Zhang Y, Lim KL, Tanaka Y, Huang H, Gao J, Ross CA, Dawson VL, Dawson TM: Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med. 2001, 7: 1144-1150. 10.1038/nm1001-1144.CrossRefPubMed
36.
Petrucelli L, O'Farrell C, Lockhart PJ, Baptista M, Kehoe K, Vink L, Choi P, Wolozin B, Farrer M, Hardy J, Cookson MR: Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron. 2002, 36: 1007-1019. 10.1016/S0896-6273(02)01125-X.CrossRefPubMed
37.
Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, Mizuno Y, Kosik KS, Selkoe DJ: Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science (New York, NY). 2001, 293: 263-269. 10.1126/science.1060627.CrossRef
38.
Yagi T, Kosakai A, Ito D, Okada Y, Akamatsu W, Nihei Y, Nabetani A, Ishikawa F, Arai Y, Hirose N, et al: Establishment of induced pluripotent stem cells from centenarians for neurodegenerative disease research. PLoS One. 2012, 7: e41572-10.1371/journal.pone.0041572.PubMedCentralCrossRefPubMed
39.
Hargus G, Cooper O, Deleidi M, Levy A, Lee K, Marlow E, Yow A, Soldner F, Hockemeyer D, Hallett PJ, et al: Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proc Natl Acad Sci USA. 2010, 107: 15921-15926. 10.1073/pnas.1010209107.PubMedCentralCrossRefPubMed
40.
Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, Lensch MW, Cowan C, Hochedlinger K, Daley GQ: Disease-Specific Induced Pluripotent Stem Cells. Cell. 2008
41.
Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, Hargus G, Blak A, Cooper O, Mitalipova M, et al: Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell. 2009, 136: 964-977. 10.1016/j.cell.2009.02.013.PubMedCentralCrossRefPubMed
42.
Devine MJ, Ryten M, Vodicka P, Thomson AJ, Burdon T, Houlden H, Cavaleri F, Nagano M, Drummond NJ, Taanman JW, et al: Parkinson's disease induced pluripotent stem cells with triplication of the alpha-synuclein locus. Nat Commun. 2011, 2: 440-PubMedCentralCrossRefPubMed
43.
Suemori H, Yasuchika K, Hasegawa K, Fujioka T, Tsuneyoshi N, Nakatsuji N: Efficient establishment of human embryonic stem cell lines and long-term maintenance with stable karyotype by enzymatic bulk passage. Biochem Biophys Res Commun. 2006, 345: 926-932. 10.1016/j.bbrc.2006.04.135.CrossRefPubMed
44.
Okada Y, Matsumoto A, Shimazaki T, Enoki R, Koizumi A, Ishii S, Itoyama Y, Sobue G, Okano H: Spatiotemporal recapitulation of central nervous system development by murine embryonic stem cell-derived neural stem/progenitor cells. Stem cells (Dayton, Ohio). 2008, 26: 3086-3098. 10.1634/stemcells.2008-0293.CrossRef
45.
Koike M, Shibata M, Waguri S, Yoshimura K, Tanida I, Kominami E, Gotow T, Peters C, von Figura K, Mizushima N, et al: Participation of autophagy in storage of lysosomes in neurons from mouse models of neuronal ceroid-lipofuscinoses (Batten disease). Am J Pathol. 2005, 167: 1713-1728. 10.1016/S0002-9440(10)61253-9.PubMedCentralCrossRefPubMed
46.
Mitsui J, Takahashi Y, Goto J, Tomiyama H, Ishikawa S, Yoshino H, Minami N, Smith DI, Lesage S, Aburatani H, et al: Mechanisms of genomic instabilities underlying two common fragile-site-associated loci, PARK2 and DMD, in germ cell and cancer cell lines. Am J Hum Genet. 2010, 87: 75-89. 10.1016/j.ajhg.2010.06.006.PubMedCentralCrossRefPubMed
Metadata
Title
Mitochondrial dysfunction associated with increased oxidative stress and α-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue
Authors
Yoichi Imaizumi
Yohei Okada
Wado Akamatsu
Masato Koike
Naoko Kuzumaki
Hideki Hayakawa
Tomoko Nihira
Tetsuro Kobayashi
Manabu Ohyama
Shigeto Sato
Masashi Takanashi
Manabu Funayama
Akiyoshi Hirayama
Tomoyoshi Soga
Takako Hishiki
Makoto Suematsu
Takuya Yagi
Daisuke Ito
Arifumi Kosakai
Kozo Hayashi
Masanobu Shouji
Atsushi Nakanishi
Norihiro Suzuki
Yoshikuni Mizuno
Noboru Mizushima
Masayuki Amagai
Yasuo Uchiyama
Hideki Mochizuki
Nobutaka Hattori
Hideyuki Okano
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Molecular Brain / Issue 1/2012
Electronic ISSN: 1756-6606
DOI
https://doi.org/10.1186/1756-6606-5-35

Other articles of this Issue 1/2012

Molecular Brain 1/2012 Go to the issue

Short report

Roles of CREB in the regulation of FMRP by group I metabotropic glutamate receptors in cingulate cortex

Research

Loss of glutathione homeostasis associated with neuronal senescence facilitates TRPM2 channel activation in cultured hippocampal pyramidal neurons

Short report

The Brugada syndrome mutation A39V does not affect surface expression of neuronal rat Cav1.2 channels

Review

Alzheimer’s disease Aβ assemblies mediating rapid disruption of synaptic plasticity and memory

Research

Activation of c-jun N-terminal kinase in spinal cord contributes to breast cancer induced bone pain in rats

Research

A series of N-terminal epitope tagged Hdh knock-in alleles expressing normal and mutant huntingtin: their application to understanding the effect of increasing the length of normal huntingtin’s polyglutamine stretch on CAG140 mouse model pathogenesis